List of CureVac patents

Patents where

Current Assignee

Name

CureVac

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10369216 Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant	Patent 10369216 was granted and assigned to CureVac on August, 2019 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10369216	August 6, 2019
‌ US Patent 11110166 Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant	Patent 11110166 was granted and assigned to CureVac on September, 2021 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11110166	September 7, 2021
‌ US Patent 8968746 Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation	Patent 8968746 was granted and assigned to CureVac on March, 2015 by the United States Patent and Trademark Office.		CureVac	United States Patent and Trademark Office	8968746	March 3, 2015
‌ US Patent 11241493 Coronavirus vaccine	Patent 11241493 was granted and assigned to CureVac on February, 2022 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11241493	February 8, 2022
‌ US Patent 9447431 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein	Patent 9447431 was granted and assigned to CureVac on September, 2016 by the United States Patent and Trademark Office.		CureVac	United States Patent and Trademark Office	9447431	September 20, 2016
‌ US Patent 10111968 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein	Patent 10111968 was granted and assigned to CureVac on October, 2018 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10111968	October 30, 2018
‌ US Patent 9669089 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen	Patent 9669089 was granted and assigned to CureVac on June, 2017 by the United States Patent and Trademark Office.		CureVac	United States Patent and Trademark Office	9669089	June 6, 2017
‌ US Patent 10188748 Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions	Patent 10188748 was granted and assigned to CureVac on January, 2019 by the United States Patent and Trademark Office.		CureVac	United States Patent and Trademark Office	10188748	January 29, 2019
‌ US Patent 9572874 Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof	Patent 9572874 was granted and assigned to CureVac on February, 2017 by the United States Patent and Trademark Office.		CureVac	United States Patent and Trademark Office	9572874	February 21, 2017
‌ US Patent 11471525 Coronavirus vaccine	Patent 11471525 was granted and assigned to CureVac on October, 2022 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11471525	October 18, 2022
‌ US Patent 11149278 Artificial nucleic acid molecules for improved protein expression	Patent 11149278 was granted and assigned to CureVac on October, 2021 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11149278	October 19, 2021
‌ US Patent 9402887 Composition for treating prostate cancer (PCa)	Patent 9402887 was granted and assigned to CureVac on August, 2016 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	9402887	August 2, 2016
‌ US Patent 10912826 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen	Patent 10912826 was granted and assigned to CureVac on February, 2021 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10912826	February 9, 2021
‌ US Patent 11286492 Artificial nucleic acid molecules for improved protein expression	Patent 11286492 was granted and assigned to CureVac on March, 2022 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11286492	March 29, 2022
‌ US Patent 11661634 Method for producing RNA	Patent 11661634 was granted and assigned to CureVac on May, 2023 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11661634	May 30, 2023
‌ US Patent 10434154 Composition for treating prostate cancer (PCa)	Patent 10434154 was granted and assigned to CureVac on October, 2019 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10434154	October 8, 2019
‌ US Patent 11786590 Rotavirus vaccines	Patent 11786590 was granted and assigned to CureVac on October, 2023 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11786590	October 17, 2023
‌ US Patent 10117920 Combination of vaccination and inhibition of the PD-1 pathway	Patent 10117920 was granted and assigned to CureVac on November, 2018 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10117920	November 6, 2018
‌ US Patent 10434158 Combination of vaccination and inhibition of the PD-1 pathway	Patent 10434158 was granted and assigned to CureVac on October, 2019 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10434158	October 8, 2019
‌ US Patent 10588959 Combination vaccine	Patent 10588959 was granted and assigned to CureVac on March, 2020 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10588959	March 17, 2020
‌ US Patent 10232024 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen	Patent 10232024 was granted and assigned to CureVac on March, 2019 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10232024	March 19, 2019
‌ US Patent 10150797 Respiratory syncytial virus (RSV) vaccine	Patent 10150797 was granted and assigned to CureVac on December, 2018 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10150797	December 11, 2018
‌ US Patent 11464836 RNA for treatment or prophylaxis of a liver disease	Patent 11464836 was granted and assigned to CureVac on October, 2022 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11464836	October 11, 2022
‌ US Patent 10166283 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen	Patent 10166283 was granted and assigned to CureVac on January, 2019 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	10166283	January 1, 2019
‌ US Patent 11034729 Respiratory syncytial virus (RSV) vaccine	Patent 11034729 was granted and assigned to CureVac on June, 2021 by the United States Patent and Trademark Office.	CureVac	CureVac	United States Patent and Trademark Office	11034729	June 15, 2021

...

Results per page:

125 results

0 selected

125 results

0 selected